STOCK TITAN

Lineage Cell The - LCTX STOCK NEWS

Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.

Lineage Cell Therapeutics, Inc. (Symbol: LCTX) is a clinical-stage biotechnology company that is pioneering the development and commercialization of novel therapies designed to address degenerative diseases. With a foundation built on pluripotent cell technology, Lineage Cell's innovative approach leverages cells capable of transforming into any type of cell in the human body. This groundbreaking capability allows for therapies aimed at regenerating or replacing damaged cells and tissues, providing hope for conditions that currently have no cure.

The company's pipeline is robust and diverse, encompassing several key product candidates:

  • OpRegen: A retinal pigment epithelium transplant therapy targeting dry age-related macular degeneration, a leading cause of vision loss among the elderly.
  • OPC1: An oligodendrocyte progenitor cell therapy designed to treat acute spinal cord injuries by promoting cell replacement and recovery.
  • VAC2: An allogeneic cancer immunotherapy utilizing antigen-presenting dendritic cells to fight non-small cell lung cancer.
  • ANP1: A promising therapy involving the transplant of allogeneic auditory neuron progenitor cells to combat hearing loss.
  • PNC1: An innovative approach using allogeneic photoreceptor cell transplants aimed at treating vision loss.

Lineage Cell Therapeutics is committed to addressing large unmet medical needs through its cutting-edge technologies. The company's clinical-stage programs are supported by a premier collection of pluripotent cell assets, positioning it at the forefront of regenerative medicine.

Recent achievements include significant progress in clinical trials, strategic partnerships, and advancements in their product development pipeline. Financially, the company remains poised for growth with a clear focus on expanding its therapeutic offerings and enhancing shareholder value.

Stay informed with the latest updates and developments at Lineage Cell Therapeutics as they continue to advance their mission of transforming the treatment landscape for degenerative diseases.

Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) has announced a registered direct offering of 13,461,540 common shares at an offering price of $1.04 per share. The agreement with investors was entered into before the markets opened on February 6, 2024. The closing of the offering is expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.73%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) announced positive results from a Phase 1/2a clinical study for OpRegen in treating geographic atrophy (GA) secondary to advanced age-related macular degeneration (AMD). The study showed retinal structure improvements, with the data set to be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting. The virtual meeting, sponsored by the University of Miami Health System Bascom Palmer Eye Institute, will feature the presentation by Allen Ho, MD, FACS, FASRS, on behalf of Roche and Genentech.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) submits an Investigational New Drug amendment (INDa) to the U.S. FDA for OPC1, its allogeneic oligodendrocyte progenitor cell transplant, for spinal cord injury treatment. The company plans to initiate the DOSED clinical study to evaluate the safety and utility of a novel spinal cord delivery device. OPC1 aims to improve the quality of life and restore functional activity in traumatic cervical or thoracic SCI patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.48%
Tags
none
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) reported financial and operating results, including updates on the Phase 2a clinical study of RG6501 (OpRegen®) in patients with Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) under management of Genentech, a Member of the Roche Group. The company also presented additional OpRegen data at the 23rd Annual EURETINA Congress and 2023 Eyecelerator Meetings. Key highlights include rapid improvement in outer retinal structure in patients, U.S. Patent issuance for manufacturing and differentiation process for retinal pigment epithelial (RPE) cells, and ongoing development activities for OPC1 and a hypoimmune pluripotent cell line for neurology indications in partnership with Eterna Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. will report its third quarter 2023 financial and operating results on November 9, 2023. A conference call and webcast will be held to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences earnings
-
Rhea-AI Summary
Lineage Cell Therapeutics to present at Eyecelerator 2023 and announces positive results from clinical study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
Rhea-AI Summary
Lineage Cell Therapeutics announces issuance of U.S. Patent for Large Scale Production of Retinal Pigment Epithelial Cells
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
-
Rhea-AI Summary
Lineage Cell Therapeutics presents positive results of Phase 1/2a study of OpRegen at EURETINA Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics CEO to present at Cantor Fitzgerald 2023 Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
conferences
Rhea-AI Summary
Lineage Cell Therapeutics announces positive results from Phase 1/2a study of RG6501 (OpRegen) in treating age-related macular degeneration (AMD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags

FAQ

What is the current stock price of Lineage Cell The (LCTX)?

The current stock price of Lineage Cell The (LCTX) is $0.676 as of February 21, 2025.

What is the market cap of Lineage Cell The (LCTX)?

The market cap of Lineage Cell The (LCTX) is approximately 158.3M.

What does Lineage Cell Therapeutics, Inc. specialize in?

Lineage Cell Therapeutics specializes in developing and commercializing novel cell therapies for treating degenerative diseases.

What are the main product candidates of Lineage Cell Therapeutics?

The main product candidates include OpRegen, OPC1, VAC2, ANP1, and PNC1.

What is OpRegen?

OpRegen is a retinal pigment epithelium transplant therapy aimed at treating dry age-related macular degeneration.

How does Lineage Cell Therapeutics utilize pluripotent cells?

Lineage Cell Therapeutics uses pluripotent cells capable of becoming any cell type to regenerate or replace affected cells and tissues.

What is OPC1 designed to treat?

OPC1 is an oligodendrocyte progenitor cell therapy for treating acute spinal cord injuries.

What type of cancer is VAC2 targeting?

VAC2 targets non-small cell lung cancer using allogeneic cancer immunotherapy.

What recent achievements has Lineage Cell Therapeutics made?

Recent achievements include progress in clinical trials, strategic partnerships, and advancements in their product development pipeline.

What is ANP1?

ANP1 is a therapy involving the transplant of allogeneic auditory neuron progenitor cells to treat hearing loss.

What is the financial outlook of Lineage Cell Therapeutics?

Lineage Cell Therapeutics is focused on growth, expanding its therapeutic offerings, and enhancing shareholder value.

Where can I find the latest updates on Lineage Cell Therapeutics?

The latest updates and developments can be found on their website and through financial news platforms.
Lineage Cell The

NYSE:LCTX

LCTX Rankings

LCTX Stock Data

158.33M
219.80M
0.44%
50.56%
8.44%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CARLSBAD